{"Ticker": "ABT", "Company": "Abbott Laboratories", "Sector": "Health Care", "Updated": "2023-07-21", "Rating": [{"Date": "2023-07-21", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Underperform to Peer Perform", "Target_Change": ""}, {"Date": "2023-05-30", "Rating": "Downgrade", "Organization": "Morgan Stanley", "Rating_Change": "Overweight to Equal-Weight", "Target_Change": "$112"}, {"Date": "2023-04-20", "Rating": "Reiterated", "Organization": "Wolfe Research", "Rating_Change": "Underperform", "Target_Change": "$107 to $103"}, {"Date": "2023-04-20", "Rating": "Reiterated", "Organization": "UBS", "Rating_Change": "Buy", "Target_Change": "$117 to $130"}, {"Date": "2023-04-20", "Rating": "Reiterated", "Organization": "Raymond James", "Rating_Change": "Outperform", "Target_Change": "$116 to $123"}, {"Date": "2023-04-20", "Rating": "Reiterated", "Organization": "JP Morgan", "Rating_Change": "Overweight", "Target_Change": "$118 to $122"}, {"Date": "2023-04-20", "Rating": "Reiterated", "Organization": "Bernstein", "Rating_Change": "Outperform", "Target_Change": "$132 to $133"}, {"Date": "2023-04-20", "Rating": "Reiterated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$125 to $127"}, {"Date": "2023-03-29", "Rating": "Initiated", "Organization": "UBS", "Rating_Change": "Buy", "Target_Change": "$117"}, {"Date": "2022-10-26", "Rating": "Initiated", "Organization": "Mizuho", "Rating_Change": "Neutral", "Target_Change": "$105"}, {"Date": "2022-10-18", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$118"}, {"Date": "2022-10-12", "Rating": "Initiated", "Organization": "Jefferies", "Rating_Change": "Hold", "Target_Change": "$110"}, {"Date": "2022-07-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Underperform", "Target_Change": "$95"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$140"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "UBS", "Rating_Change": "Buy", "Target_Change": "$138 to $142"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Raymond James", "Rating_Change": "Outperform", "Target_Change": "$150 to $143"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$157 to $151"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Credit Suisse", "Rating_Change": "Outperform", "Target_Change": "$138 to $139"}, {"Date": "2021-12-10", "Rating": "Initiated", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform", "Target_Change": "$146"}, {"Date": "2021-10-27", "Rating": "Upgrade", "Organization": "Atlantic Equities", "Rating_Change": "Neutral to Overweight", "Target_Change": "$144"}, {"Date": "2021-10-14", "Rating": "Initiated", "Organization": "Redburn", "Rating_Change": "Neutral", "Target_Change": ""}, {"Date": "2021-05-25", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$150"}, {"Date": "2021-04-15", "Rating": "Initiated", "Organization": "Atlantic Equities", "Rating_Change": "Neutral", "Target_Change": "$122"}, {"Date": "2021-01-28", "Rating": "Upgrade", "Organization": "BTIG Research", "Rating_Change": "Neutral to Buy", "Target_Change": "$140"}, {"Date": "2020-09-11", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Outperform", "Target_Change": "$124"}, {"Date": "2020-06-01", "Rating": "Downgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Sell", "Target_Change": "$84"}, {"Date": "2020-03-05", "Rating": "Initiated", "Organization": "Citigroup", "Rating_Change": "Buy", "Target_Change": "$96"}, {"Date": "2020-02-13", "Rating": "Initiated", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": "$96"}, {"Date": "2020-02-06", "Rating": "Resumed", "Organization": "BTIG Research", "Rating_Change": "Neutral", "Target_Change": ""}, {"Date": "2020-01-02", "Rating": "Downgrade", "Organization": "Guggenheim", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2019-06-13", "Rating": "Reiterated", "Organization": "BofA/Merrill", "Rating_Change": "Buy", "Target_Change": "$81 to $90"}, {"Date": "2019-02-07", "Rating": "Reiterated", "Organization": "BofA/Merrill", "Rating_Change": "Buy", "Target_Change": "$73 to $81"}, {"Date": "2019-01-02", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Sell", "Target_Change": ""}, {"Date": "2018-11-30", "Rating": "Upgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2018-10-16", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$80"}, {"Date": "2018-06-27", "Rating": "Initiated", "Organization": "Bernstein", "Rating_Change": "Outperform", "Target_Change": "$73"}, {"Date": "2018-01-30", "Rating": "Reiterated", "Organization": "Citigroup", "Rating_Change": "Neutral", "Target_Change": "$59 to $64"}, {"Date": "2018-01-25", "Rating": "Upgrade", "Organization": "William Blair", "Rating_Change": "Mkt Perform to Outperform", "Target_Change": ""}]}